Eli Lilly's biggest shareholder, the Lilly Endowment, filed to sell 300,000 shares worth $347 million, driven by a legal payout requirement rather than company performance concerns. Despite the sale, analysts continue to raise price targets, with Morgan Stanley and Cantor Fitzgerald increasing their targets to around $1,430-$1,440. Lilly's strong market position in GLP-1 drugs and robust revenue growth support these positive outlooks, although pricing pressures in the U.S. remain a challenge. The sale represents a small fraction of the Endowment's holdings and is unlikely to impact the stock's long-term value, which analysts still view as undervalued relative to growth prospects.
Eli Lilly's stock is trading at USD 1,170.00 on Pluang as of Oct 09, 2026 20:31 WIB, showing a minimal 1-day change of +0.01%. The stock's market cap stands at $1.04 trillion, reflecting its significant size in the health sector. Despite the shareholder's sale, Pluang users show a strong buying interest with 69% of order activity favoring buys.
Cantor Fitzgerald increased price targets for four major pharmaceutical companies: Eli Lilly, AbbVie, Merck, and Pfizer, while maintaining their current ratings. Eli Lilly and AbbVie received Overweight ratings with higher targets, reflecting stronge...
Eli Lilly's Phase 3b TOGETHER-PsO trial revealed that combining Taltz (ixekizumab) and Zepbound (tirzepatide) led to broader changes in psoriasis and metabolic biomarkers compared to Taltz alone as early as Week 12. This suggests a linked immune-meta...
At the Veeva R&D and Quality Summit in Boston, leading biopharma companies like Eli Lilly, Pfizer, and Sanofi shared innovations in AI, cloud platforms, and connected trials to accelerate drug development and improve quality. Highlights include Eli L...
Novo Nordisk is rated as a Buy compared to Eli Lilly because it trades at a significant valuation discount of about 26% to its big pharma peers despite having similar growth rates and a strong dividend yield. The stock is priced at roughly 11.2 times...
Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...
